Meeting
2022 ASCO Quality Care Symposium
Impact of statin type and intensity on cisplatin-related hearing loss.
Authors
Emilee McCullough
F&MCW Clinical Cancer Center, Milwaukee, WI
Emilee McCullough, Aditya V. Shreenivas, Stephanie Spitzer, Michelle Schroeder, Aniko Szabo, David Friedland, Stuart J. Wong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 192)
DOI
10.1200/JCO.2022.40.28_suppl.192
Abstract #
192
Poster Bd #
A17
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Quality Care Symposium
Barriers and facilitators to the implementation of routine ototoxicity screening for head and neck cancer patients.
First Author: Priya Bapat
Poster
2022 ASCO Annual Meeting
Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in the T4a cohort.
First Author: Akihiro Homma
Poster
2021 Genitourinary Cancers Symposium
DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma.
First Author: Simon J. Crabb
First Author: Callie Berkowitz